Drug Trial Radar · NCT07875881
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,044
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Hinova Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer after definitive therapy.
Conditions
- High Risk Biochemical Recurrence (BCR)
- Deutenzalutamide Soft Capsules
Interventions
Deutenzalutamide Soft Capsules + ADTDrug
Deutenzalutamide Soft Capsules 80mg(Two capsules),QD, oral; ADT (Goserelin Acetate Sustained-release Implant) 10.8mg per dose, administered once every 12 weeks
Placebo + ADTDrug
Placebo Two capsules,QD, oral; ADT (Goserelin Acetate Sustained-release Implant) 10.8mg per dose, administered once every 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- MFS evaluated by BICRTime frame: Baseline, Week 25, 49 and every 24 weeks thereafter (± 5 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.